223 related articles for article (PubMed ID: 17516639)
1. Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokinin-1 receptor antagonists.
Yamamoto T; Nair P; Davis P; Ma SW; Navratilova E; Moye S; Tumati S; Lai J; Vanderah TW; Yamamura HI; Porreca F; Hruby VJ
J Med Chem; 2007 Jun; 50(12):2779-86. PubMed ID: 17516639
[TBL] [Abstract][Full Text] [Related]
2. A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.
Yamamoto T; Nair P; Vagner J; Largent-Milnes T; Davis P; Ma SW; Navratilova E; Moye S; Tumati S; Lai J; Yamamura HI; Vanderah TW; Porreca F; Hruby VJ
J Med Chem; 2008 Mar; 51(5):1369-76. PubMed ID: 18266313
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.
Agnes RS; Lee YS; Davis P; Ma SW; Badghisi H; Porreca F; Lai J; Hruby VJ
J Med Chem; 2006 May; 49(10):2868-75. PubMed ID: 16686530
[TBL] [Abstract][Full Text] [Related]
4. Improving metabolic stability by glycosylation: bifunctional peptide derivatives that are opioid receptor agonists and neurokinin 1 receptor antagonists.
Yamamoto T; Nair P; Jacobsen NE; Vagner J; Kulkarni V; Davis P; Ma SW; Navratilova E; Yamamura HI; Vanderah TW; Porreca F; Lai J; Hruby VJ
J Med Chem; 2009 Aug; 52(16):5164-75. PubMed ID: 20560643
[TBL] [Abstract][Full Text] [Related]
5. Novel ligands lacking a positive charge for the delta- and mu-opioid receptors.
Schiller PW; Berezowska I; Nguyen TM; Schmidt R; Lemieux C; Chung NN; Falcone-Hindley ML; Yao W; Liu J; Iwama S; Smith AB; Hirschmann R
J Med Chem; 2000 Feb; 43(4):551-9. PubMed ID: 10691681
[TBL] [Abstract][Full Text] [Related]
6. Development of potent bifunctional endomorphin-2 analogues with mixed mu-/delta-opioid agonist and delta-opioid antagonist properties.
Fujita Y; Tsuda Y; Li T; Motoyama T; Takahashi M; Shimizu Y; Yokoi T; Sasaki Y; Ambo A; Kita A; Jinsmaa Y; Bryant SD; Lazarus LH; Okada Y
J Med Chem; 2004 Jul; 47(14):3591-9. PubMed ID: 15214786
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists.
Lee YS; Agnes RS; Badghisi H; Davis P; Ma SW; Lai J; Porreca F; Hruby VJ
J Med Chem; 2006 Mar; 49(5):1773-80. PubMed ID: 16509592
[TBL] [Abstract][Full Text] [Related]
8. Side chain methyl substitution in the delta-opioid receptor antagonist TIPP has an important effect on the activity profile.
Tourwé D; Mannekens E; Diem TN; Verheyden P; Jaspers H; Tóth G; Péter A; Kertész I; Török G; Chung NN; Schiller PW
J Med Chem; 1998 Dec; 41(26):5167-76. PubMed ID: 9857087
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological activities of cyclic lanthionine enkephalin analogues: delta-opioid receptor selective ligands.
Rew Y; Malkmus S; Svensson C; Yaksh TL; Chung NN; Schiller PW; Cassel JA; DeHaven RN; Taulane JP; Goodman M
J Med Chem; 2002 Aug; 45(17):3746-54. PubMed ID: 12166947
[TBL] [Abstract][Full Text] [Related]
10. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
[TBL] [Abstract][Full Text] [Related]
11. Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists.
Tóth G; Ioja E; Tömböly C; Ballet S; Tourwé D; Péter A; Martinek T; Chung NN; Schiller PW; Benyhe S; Borsodi A
J Med Chem; 2007 Jan; 50(2):328-33. PubMed ID: 17228874
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain.
Giri AK; Apostol CR; Wang Y; Forte BL; Largent-Milnes TM; Davis P; Rankin D; Molnar G; Olson KM; Porreca F; Vanderah TW; Hruby VJ
J Med Chem; 2015 Nov; 58(21):8573-83. PubMed ID: 26465170
[TBL] [Abstract][Full Text] [Related]
13. Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin 1 receptor antagonists possessing two penicillamines.
Yamamoto T; Nair P; Jacobsen NE; Kulkarni V; Davis P; Ma SW; Navratilova E; Yamamura HI; Vanderah TW; Porreca F; Lai J; Hruby VJ
J Med Chem; 2010 Aug; 53(15):5491-501. PubMed ID: 20617791
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
15. Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands.
Li T; Shiotani K; Miyazaki A; Tsuda Y; Ambo A; Sasaki Y; Jinsmaa Y; Marczak E; Bryant SD; Lazarus LH; Okada Y
J Med Chem; 2007 Jun; 50(12):2753-66. PubMed ID: 17497839
[TBL] [Abstract][Full Text] [Related]
16. Development of potent μ and δ opioid agonists with high lipophilicity.
Lee YS; Kulkarani V; Cowell SM; Ma SW; Davis P; Hanlon KE; Vanderah TW; Lai J; Porreca F; Vardanyan R; Hruby VJ
J Med Chem; 2011 Jan; 54(1):382-6. PubMed ID: 21128594
[TBL] [Abstract][Full Text] [Related]
17. Truncation of the peptide sequence in bifunctional ligands with mu and delta opioid receptor agonist and neurokinin 1 receptor antagonist activities.
Nair P; Yamamoto T; Largent-Milnes TM; Cowell S; Kulkarni V; Moye S; Navratilova E; Davis P; Ma SW; Vanderah TW; Lai J; Porreca F; Hruby VJ
Bioorg Med Chem Lett; 2013 Sep; 23(17):4975-8. PubMed ID: 23899615
[TBL] [Abstract][Full Text] [Related]
18. Discovery of tripeptide-derived multifunctional ligands possessing delta/mu opioid receptor agonist and neurokinin 1 receptor antagonist activities.
Nair P; Yamamoto T; Cowell S; Kulkarni V; Moye S; Navratilova E; Davis P; Ma SW; Vanderah TW; Lai J; Porreca F; Hruby VJ
Bioorg Med Chem Lett; 2015 Sep; 25(17):3716-20. PubMed ID: 26212775
[TBL] [Abstract][Full Text] [Related]
19. Development of novel enkephalin analogues that have enhanced opioid activities at both mu and delta opioid receptors.
Lee YS; Petrov R; Park CK; Ma SW; Davis P; Lai J; Porreca F; Vardanyan R; Hruby VJ
J Med Chem; 2007 Nov; 50(22):5528-32. PubMed ID: 17927164
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis.
Mollica A; Guardiani G; Davis P; Ma SW; Porreca F; Lai J; Mannina L; Sobolev AP; Hruby VJ
J Med Chem; 2007 Jun; 50(13):3138-42. PubMed ID: 17539621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
